Yervoy (ipilimumab) / BMS 
Welcome,         Profile    Billing    Logout  
 197 Diseases   398 Trials   398 Trials   21826 News 


«12345678910111213...266267»
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Journal, PD(L)-1 Biomarker, IO biomarker, Metastases:  Management of overlapping immune-related myocarditis, myositis, and myasthenia in a young patient with advanced NSCLC: a case report. (Pubmed Central) -  Oct 28, 2024   
    A 40-year-old patient, diagnosed with stage IV non-oncogene addicted lung adenocarcinoma, with nivolumab-ipilimumab-chemotherapy as first-line treatment, developed a rare myocarditis-myositis-myasthenia gravis overlap syndrome...Treatment with oral prednisone, pyridostigmine, and IV Igs was started due to poor clinical response followed by methylprednisolone...This report aims to raise awareness among physicians about these serious side effects. A multidisciplinary approach led to clinical improvement and early intervention, optimizing patient outcomes.
  • ||||||||||  5-fluorouracil / Generic mfg.
    Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker:  Chemotherapy combined with immune checkpoint inhibitors may overcome the detrimental effect of high neutrophil-to-lymphocyte ratio prior to treatment in esophageal cancer patients. (Pubmed Central) -  Oct 28, 2024   
    We retrospectively analyzed the outcomes of combination therapy, including nivolumab plus ipilimumab or chemotherapy plus anti-programmed cell death 1 (PD-1) antibodies in our institute to identify biomarkers...In multivariable analysis, albumin level was significantly correlated with PFS in the cisplatin plus 5-fluorouracil (CF) plus pembrolizumab group...In chemotherapy combined with ICIs, NLR before the treatment was not associated with treatment efficacy, suggesting combination chemotherapy may be beneficial for EC patients with high NLR. NLR may be an indicator of immunocompetence in anti-tumor immunity and a convenient predictive biomarker for selecting appropriate treatments including ICIs.
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial completion date, Trial primary completion date:  CA209-8H3: Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients (clinicaltrials.gov) -  Oct 27, 2024   
    P2,  N=30, Active, not recruiting, 
    NLR may be an indicator of immunocompetence in anti-tumor immunity and a convenient predictive biomarker for selecting appropriate treatments including ICIs. Trial completion date: Apr 2026 --> Jan 2026 | Trial primary completion date: Aug 2024 --> Jan 2025
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Journal, Real-world evidence, Real-world:  Safety and Efficacy of Nivolumab plus Ipilimumab Therapy-Our Real World Experience (Pubmed Central) -  Oct 27, 2024   
    In the study of 64 cases with multiple cancer, higher efficacy of ICI combined therapy was expected in cases with irAEs, and there were cases with long-lasting efficacy even after early discontinuation of ipilimumab due to irAEs. And the high dose(3 mg/kg)of ipilimumab was suggested to be an independent risk factor for CTCAE Grade 3 or higher for severe irAEs.
  • ||||||||||  LNS8801 / Linnaeus Therap
    Phase classification:  A Trial of LNS8801 with or Without Pembrolizumab in Patients with Refractory Melanoma (clinicaltrials.gov) -  Oct 27, 2024   
    P2/3,  N=135, Not yet recruiting, 
    And the high dose(3 mg/kg)of ipilimumab was suggested to be an independent risk factor for CTCAE Grade 3 or higher for severe irAEs. Phase classification: P3 --> P2/3
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker, Metastases:  Exploring the Frequency and Risk Factors of Hyperprogressive Disease in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors. (Pubmed Central) -  Oct 25, 2024   
    Multivariate analysis identified the Royal Marsden Hospital score (HR 3.675, 95% CI: 1.166-11.580, p = 0.026) as an independent risk factor for HPD, with the MDA-ICI score also trending towards significance (HR 4.466, 95% CI: 0.947-21.061, p = 0.059). This study provides valuable insights into the frequency and factors associated with HPD in advanced melanoma patients treated with ICIs, highlighting the relevance of clinical markers and scoring systems in predicting HPD risk.
  • ||||||||||  Opdivo (nivolumab) / BMS, vidutolimod (CMP-001) / Regeneron
    Biomarker, Trial completion, Trial completion date, Trial primary completion date:  Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab (clinicaltrials.gov) -  Oct 21, 2024   
    P2,  N=9, Completed, 
    Changes in tumor size and immune cell infiltration and activation are candidate predictive markers of pathologic response to neoadjuvant immunotherapy in patients with resectable HCC. Active, not recruiting --> Completed | Trial completion date: Jul 2028 --> Aug 2024 | Trial primary completion date: Jul 2028 --> Aug 2024
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial initiation date, Checkpoint inhibition:  DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC (clinicaltrials.gov) -  Oct 17, 2024   
    P2,  N=24, Not yet recruiting, 
    Suspended --> Recruiting Initiation date: Oct 2024 --> Jan 2025
  • ||||||||||  Clinical, Retrospective data, Review, Journal, Checkpoint inhibition:  Immune Checkpoint Inhibitor-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis. (Pubmed Central) -  Oct 17, 2024   
    Incidence of CVAEs following ipilimumab treatment was 1.07% (95% CI, 0%-2.58%)...Prospective data from 40 patients with myocarditis indicated that systematic screening for respiratory muscle involvement, coupled with active ventilation, prompt use of abatacept, and the addition of ruxolitinib, may decrease the mortality rate...Early recognition, ICI therapy cessation, prompt initiation of corticosteroid therapy, and escalation of therapy are all crucial elements for achieving optimal outcomes. Prospective clinical trials or at least prospective registration of treatments and outcomes are highly warranted.
  • ||||||||||  Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Review, Journal:  Systemic Therapy Options for Peritoneal Mesothelioma. (Pubmed Central) -  Oct 17, 2024   
    At present, the recommended first-line systemic treatment options may include immunotherapy with nivolumab plus ipilimumab or chemotherapy with pemetrexed plus either cisplatin or carboplatin...Off-label bevacizumab may be considered in combination with chemotherapy among carefully selected patients...In summary, there is a growing number of systemic therapy options for peritoneal mesothelioma. To gain a better insight into this disease, future prospective trials in mesothelioma should include more patients with peritoneal mesothelioma.
  • ||||||||||  Yervoy (ipilimumab) / BMS
    Journal, Real-world evidence, PD(L)-1 Biomarker, IO biomarker, Real-world, Metastases:  Survival of Patients with Metastatic Melanoma Treated with Ipilimumab after PD-1 Inhibitors: A Single-Center Real-World Study. (Pubmed Central) -  Oct 16, 2024   
    To gain a better insight into this disease, future prospective trials in mesothelioma should include more patients with peritoneal mesothelioma. In case of failure to enroll patients in innovative clinical trials, second-line ipilimumab still represents an effective therapy in patients with metastatic wildtype melanoma and in the absence of brain metastases.
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial completion, Trial completion date, Trial primary completion date, Checkpoint inhibition:  CheckPRO: Checkpoint Inhibitors and SBRT for MCRPC (clinicaltrials.gov) -  Oct 16, 2024   
    P2,  N=90, Completed, 
    In case of failure to enroll patients in innovative clinical trials, second-line ipilimumab still represents an effective therapy in patients with metastatic wildtype melanoma and in the absence of brain metastases. Recruiting --> Completed | Trial completion date: Jan 2025 --> Aug 2024 | Trial primary completion date: Jan 2024 --> Aug 2024
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    THE METAHEPS () -  Oct 15, 2024 - Abstract #AASLD2024AASLD_1938;    
    A single causative drug (terbinafine, ibuprofen) was determined by adjudication in only two cases...In three patients in whom adjudication could not determine a single causative drug, the LDH values from DILI-derived MH were higher than ULN in response to nivolumab, amoxicillin or ipilimumab, respectively... The MetaHeps
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Journal, Checkpoint inhibition:  Immune checkpoint inhibitor-associated sick sinus syndrome and cardiogenic shock. (Pubmed Central) -  Oct 14, 2024   
    However, the conclusion emphasized the need for further prospective clinical trials to validate these results. Herein we discussed a 67-year-old, male, Japanese patient who presented with cardiogenic shock accompanied by sick sinus syndrome 4
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Tumor board for immunotherapy-mediated side effects  (Osaka/Samarkand) -  Oct 13, 2024 - Abstract #DGHO2024DGHO_1473;    
    Especially cancer patients suffering from rare and/or steroid-dependent/-refractory IrAEs should be discussed in a multidisciplinary tumor board for optimal IrAE therapy and the possibility to resume ICI-therapy. Establishing an IrAE registry, analyzing immune cell populations and implementing clinical studies for therapy optimization holds great potential to improve IrAE patient care in future.
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Effect of different combinations of potentially immunogenic therapeutics on the T cell response in acute myeloid leukemia (Rio) -  Oct 13, 2024 - Abstract #DGHO2024DGHO_997;    
    Upon considering only the responders, several reduction rates were even higher, with anti-PD-1 39%; AZA at 57%; and anti-PD-1+AZA at 66% and for Len/anti-PD-1+Len 57/59%. Taken together, combinations of immunotherapeutic approaches increase antigen-specific immune responses against leukemic cells especially the combination of LAA-Peptides with the anti-PD-1 antibody and one further immunomodulating drug, like AZA, could be an interesting option for further studies.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Journal, Adverse events:  Impact of immune-related adverse events on survival among patients with head-and-neck squamous cell carcinoma. (Pubmed Central) -  Oct 11, 2024   
    Development of irAE was associated with superior objective response rate, with a greater rate of CR and PR. ICI re-treatment following irAE was feasible in a significant proportion of patients and can be attempted in carefully selected patients, given the dearth of second-line therapies for these patients.